Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Codeine Linctus BP
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Codeine phosphate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
FOR This medicine has been prescribed for you to help you stop coughing, especially if you have a non-productive cough. It contains the active codeine which belongs to a class of medicines called opioids. This medicine has been prescribed to you and should not be given to anyone else.
Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, and how to do this safely.
What you need to know before you take it
E CODEINE LINCTUS Do not take Codeine Linctus if you:
- are allergic (hypersensitive) to Codeine or any of the other ingredients listed (see Section 6 and end of Section 2)
- have liver disease
- have breathing problems (i.e. ventilatory failure)
- know that you metabolise very rapidly codeine into morphine
- are breast-feeding
- are under 12 years old. Adolescents older than 12 years of age Codeine is not recommended in adolescents with compromised respiratory function for the treatment of cough. Warnings and precautions Tolerance, dependence, and addiction This medicine contains codeine which is an opioid medicine. It can cause dependence and/or addiction. Repeated use of opioids can result in the drug being less effective (you become accustomed to it, known as tolerance). Repeated use of Codeine Linctus can also lead to dependence, abuse and addiction, which may result in life-threatening overdose. The risk of these side effects can increase with a higher dose and longer duration of use. Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it.
The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent on or addicted to Codeine Linctus if:
- you or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs ("addiction")
- you are a smoker
- you have ever had problems with your mood (depression, anxiety, or a personality disorder) or have been treated by a psychiatrist for other mental illnesses. If you notice any of the following signs whilst taking Codeine Linctus, it could be a sign that you have become dependent or addicted:
- you may need to take the medicine for longer than advised by your doctor
- you need to take more than the recommended dose
- you might feel that you need to carry on taking your medicine, even when it doesn't help to relieve your cough
- you are using the medicine for reasons other than prescribed, for instance, 'to stay calm' or 'help you sleep'
- you have made repeated, unsuccessful attempts to quit or control the use of the medicine
- when you stop taking the medicine you feel unwell, and you feel better once taking the medicine again ('withdrawal effects').
If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (see section 3, 'If you stop taking Codeine Linctus'). Sleep-related breathing disorders Codeine Linctus can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor. Take special care with Codeine Linctus or talk to your doctor or pharmacist if you have:
- asthma
- liver or kidney problems
- an under active thyroid (i.e. hypothyroidism)
- a problem of drug abuse (now or in the past) or are
- pregnant or breast-feeding Take care if giving Codeine Linctus to the elderly. Supervision of these patients is advisable.
Codeine is transformed to morphine in the liver by an enzyme. Morphine is the substance that produces the effects of codeine. Some people have a variation of this enzyme and this can affect people in different ways. In some people, morphine is not produced or produced in very small quantities, and it will not have an effect on their cough symptoms. Other people are more likely to get serious side effects because a very high amount of morphine is produced. If you notice any of the following side effects, you must stop taking this medicine and seek immediate medical advice: slow or shallow breathing, confusion, sleepiness, small pupils, feeling or being sick, constipation, lack of appetite. Contact your doctor if you experience severe upper abdominal pain possibly radiating to the back, nausea, vomiting or fever as this could be symptoms associated with inflammation of the pancreas (pancreatitis) and the biliary tract system.
Other medicines and Codeine Linctus Please tell your doctor or pharmacist if you are taking or have recently taken, any other medicines, including medicines obtained without a prescription and especially if you are taking any of the following:
- anti-depressants known as monoamine-oxidase inhibitors (MAOIs)
- CNS depressants (e.g. chlorpromazine)
- anticholinergics (e.g. oxybutynin)
- hydroxyzine
- methadone
- levallorphan
- neuromuscular blocking agents (e.g. atracurium)
- metoclopramide
- mexiletine
- hypnotics (such as sleeping tablets) and sedatives
- gabapentin or pregabalin to treat epilepsy or pain due to nerve problems (neuropathic pain). Codeine Linctus with food, drink and alcohol You must not drink alcohol while taking this medicine as this may increase drowsiness. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Do not take Codeine Linctus if you are pregnant or think you might be pregnant unless you have discussed this with your prescriber and the benefits of treatment are considered to outweigh the potential harm to the baby. If you use Codeine Linctus during pregnancy, your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated. Do not take Codeine Linctus while you are breast-feeding as codeine passes into breast milk and will affect your baby. Driving and using machines Codeine may cause drowsiness. Do not drive or operate machinery until you know how the medicine will affect you. The medicine can affect your ability to drive as it may make you sleepy or dizzy.
- Do not drive while taking this medicine until you know how it affects you.
- It is an offence to drive if this medicine affects your ability to drive.
23LF02203PW
FRONT PAGE (pg1/2)
Artwork Code:
23LF02203PW
Font:
Helvetica 8pt – 7.5pt
Date
24/02/26
Dimensions:
357 x 210 mm
Printing:
Black
***
***
***
***
***
Version:
Non-Printing:
Keyline
Print Free Area
***
***
***
***
1
Other information: Previous code – 23LF02068PW Safet updates Dimensions changed from 297x210mm to 357x210mm
- However, you would not be committing an offence if: o The medicine has been prescribed to treat a medical or dental problem and o You have taken it according to the instructions given by the prescriber or in the information provided with the medicine and o It was not affecting your ability to drive safely Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine. Important information about some of the ingredients of Codeine Linctus Codeine Linctus also contains:
- Sorbitol solution (E420): If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product
- Sunset yellow (E110): which may cause allergic reactions
- Ethanol: This medicinal product contains small amounts of ethanol (alcohol), less than 100 mg per dose.
How to take it
CODEINE LINCTUS Your prescriber should have discussed with you, how long the course of treatment will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. Codeine Linctus should be taken for the shortest duration necessary to relieve symptoms. Always take the product exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. Only to be taken by mouth. The recommended dose is: Adults
One to two 5 ml spoonfuls 3 – 4 times daily
Elderly or weak patients
Dosage should be reduced
Adolescents (12 to 18 years)
One to two 5 ml spoonfuls 3 – 4 times daily
Children (under 12 years)
Not for use in children under the age of 12 years
Do not exceed the stated dose. If you take more Codeine Linctus than you should If you or someone else takes too much Codeine Linctus, you should contact your doctor or pharmacist who will recommend what action you should take. If you forget to take Codeine Linctus If you miss a dose, take it as soon as you remember and take any remaining doses for that day at evenly spaced times. Do not take a double dose to make up for the forgotten dose. If you stop taking Codeine Linctus Do not suddenly stop taking this medicine. If you want to stop taking this medicine, discuss this with your prescriber first. They will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. Withdrawal symptoms such as restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating may occur if you suddenly stop taking this medicine. If you have any further questions on the use of this product, ask your doctor or pharmacist.
4. POSSIBLE SIDE EFFECTS Like all medicines, Codeine Linctus can cause side effects, although not everybody gets them. STOP using Codeine Linctus and seek advice from your doctor if you experience a rare allergic reaction, including skin rashes, swollen face, lips, tongue, difficulty breathing, increased sensitivity to light, inflammation of the blood vessels, fever or shock.
Possible side effects
which may occur include:
- nausea, vomiting, constipation
- loss of appetite
- flushing of face
- slow or shallow breathing
- difficulty coughing up mucous or saliva (particularly in patients with chronic bronchitis and bronchiectasis)
- dependence and addiction (frequency unknown) (see section "How do I know if I am addicted?")
- symptoms associated with inflammation of the pancreas (pancreatitis) and the biliary tract system (a problem affecting a valve in the intestines known as sphincter of Oddi dysfunction), e.g. severe upper abdominal pain possibly radiating to the back, nausea, vomiting or fever.
Drug Withdrawal When you stop taking Codeine Linctus, you may experience drug withdrawal symptoms, which include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating. How do I know if I am addicted? If you notice any of the following signs whilst taking Codeine Linctus, it could be a sign that you have become addicted.
- You need to take the medicine for longer than advised by your prescriber
- You feel you need to use more than the recommended dose
- You are using the medicine for reasons other than prescribed
- When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again If you notice any of these signs, it is important you talk to your prescriber.
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
How to store it
CODEINE LINCTUS Store this medicine in a safe and secure storage space, where other people cannot access it. It can cause serious harm and be fatal to people when it has not been intended for them. Keep this medicine out of the sight and reach of children. Do not store above 25 ̊C. Keep in the original container in order to protect from light. Do not use this product after the expiry date which is stated on the bottle. The expiry date refers to the last day of that month. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
Contents of the pack and other information
What Codeine Linctus contains
- The active ingredient is: Codeine Phosphate, 15 mg in each 5 ml
- The other ingredients are: sodium benzoate (E211), citric acid monohydrate, saccharin sodium (E954), sunset yellow (E110), sorbitol solution (E420), orange flavour, carboxymethylcellulose, propylene glycol and purified water (see end of Section 2 for further information) What Codeine Linctus looks like and contents of the pack Codeine Linctus is a clear orange syrup, with an orange flavour, available in 2000 ml and 1000 ml plastic bottles or in 100 ml, 125 ml and 200 ml amber glass bottles. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Pinewood Laboratories Ltd., Ballymacarbry, Clonmel, Co. Tipperary, Ireland. PL 04917/0001 This leaflet was last updated in 02/2026
23LF02203PW
BACK PAGE (pg2/2)
Artwork Code:
23LF02203PW
Font:
Helvetica 8pt – 7.5pt
Date
24/02/26
Dimensions:
357 x 210 mm
Printing:
Black
***
***
***
***
***
Version:
Non-Printing:
Keyline
Print Free Area
***
***
***
***
1
Other information: Previous code – 23LF02068PW Safet updates Dimensions changed from 297x210mm to 357x210mm
Frequently asked questions about Codeine Linctus BP
What is the active substance in Codeine Linctus BP?
The active substance in Codeine Linctus BP is codeine phosphate.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Codeine Linctus BP, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Codeine Linctus BP without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: codeine phosphate
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Recommended as an anti-tussive for a non productive cough by oral administration.
4.2. Posology and method of administration
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with codeine in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).
Codeine Linctus BP should not be used longer than necessary.
The usual dosage for adults is 5 to 10 ml, 3 to 4 times daily. Dosage should be reduced in elderly or debilitated patients.
Paediatric population:
Children aged less than 12 years:
Codeine is contraindicated in children below the age of 12 years (see sections 4.3).
Children aged 12 years to 18 years:
Codeine is not recommended for use in children aged 12 years to 18 years with compromised respiratory function (see section 4.4).
4.3. Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
Liver disease: drug may accumulate.
Ventilatory failure condition may be exacerbated.
In children below the age of 12 years due to an increased risk of developing serious and life threatening adverse reactions.
In women during breastfeeding (see section 4.6).
In patients for whom it is known they are CYP2D6 ultra-rapid metabolisers.
4.4. Special warnings and precautions for use
Geriatric patients should be supervised while on this medication, and consideration of reduced dosage should be based on response. Codeine should only be used with caution in patients with kidney or liver impairment. Care should be taken in patients with asthma, hypothyroidism, and in patients with a history of drug abuse. Tolerance and dependency may occur with prolonged use.
CYP2D6 metabolism
Codeine is metabolised by the liver enzyme CYP2D6 into morphine, its active metabolite. If a patient has a deficiency or is completely lacking this enzyme an adequate therapeutic effect will not be obtained. Estimates indicate that up to 7% of the Caucasian population may have this deficiency. However, if the patient is an extensive or ultra-rapid metaboliser there is an increased risk of developing side effects of opioid toxicity even at commonly prescribed doses. These patients convert codeine into morphine rapidly resulting in higher than expected serum morphine levels. General symptoms of opioid toxicity include confusion, somnolence, shallow breathing, small pupils, nausea, vomiting, constipation and lack of appetite. In severe cases this may include symptoms of circulatory and respiratory depression, which may be life-threatening and very rarely fatal. Estimates of prevalence of ultra-rapid metabolisers in different populations are summarized below:
Population
Prevalence %
African/Ethiopian
29%
African American
3.4% to 6.5%
Asian
1.2% to 2%
Caucasian
3.6% to 6.5%
Greek
6.0%
Hungarian
1.9%
Northern European
1%-2%
Children with compromised respiratory function
Codeine is not recommended for use in children in whom respiratory function might be compromised including neuromuscular disorders, severe cardiac or respiratory conditions, upper respiratory or lung infections, multiple trauma or extensive surgical procedures. These factors may worsen symptoms of morphine toxicity
Tolerance and opioid use disorder (abuse and dependence)
Tolerance, physical and psychological dependence, and opioid use disorder (OUD) may develop upon repeated administration of opioids such as [product name]. Repeated use of Codeine Linctus BP can lead to OUD. A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of Codeine Linctus BP may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).
The patient should be made aware of the risks and signs of OUD as set out in the package leaflet. If these signs occur, patients should contact their physician.
For patients who experience signs and symptoms of OUD, and/or exhibit drug seeking behaviours, review of concomitant opioids and psycho-active drugs (like benzodiazepines) and consultation with an addiction specialist may be required.
Drug withdrawal syndrome
Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with codeine.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.
Hyperalgesia
Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.
Sleep-related breathing disorders
Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.
Hepatobiliary disorders
Codeine may cause dysfunction and spasm of the sphincter of Oddi, thus increasing the risk of biliary tract symptoms and pancreatitis. Therefore, codeine has to be administered with caution in patients with pancreatitis and diseases of the biliary tract.
Sunset Yellow may cause allergic reactions.
This product contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine.
4.5. Interaction with other medicinal products and other forms of interaction
CNS depressants, anticholinergics, hydroxyzine and methadone – concurrent use of these medicines may result in potentiation of effects and hypotensive effects and CNS depressant effects may be increased; levallorphan is a morphine antagonist; the respiratory effects of neuromuscular blocking agents may be addictive to the central respiratory effects of the opioid analgesics; the concomitant use of Codeine Linctus BP with gabapentinoids (gabapentin and pregabalin) may result in respiratory depression, hypotension, profound sedation, coma or death (see section 4.4); metoclopramide and codeine have opposing effects on gastro – intestinal activity; codeine causes delayed absorption of mexiletine; the effects of hypnotics and sedatives may be potentiated by codeine; hypertensive crisis may be caused by concurrent use of codeine and monoamine – oxidase inhibitors.
4.6. Fertility, pregnancy and lactation
Pregnancy
Risk – benefit must be considered before using codeine during pregnancy. Codeine crosses the placenta and is excreted in small amounts in breast milk. Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate. Teratogenic effects in humans have not been documented but controlled studies have not been done. There is a risk of gastric stasis in the mother during labour which may lead to inhalation pneumonia.
If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.
Breastfeeding
Codeine is contraindicated in women during breastfeeding (see section 4.3).
At normal therapeutic doses codeine and its active metabolite may be present in breast milk at very low doses and is unlikely to adversely affect the breast fed infant. However, if the patient is an ultra-rapid metaboliser of CYP2D6, higher levels of the active metabolite, morphine, may be present in breast milk and on very rare occasions may result in symptoms of opioid toxicity in the infant, which may be fatal.
If symptoms of opioid toxicity develop in either the mother or the infant, then all codeine containing medicines should be stopped and alternative non-opioid analgesics prescribed. In severe cases consideration should be given to prescribing naloxone to reverse these effects.
Administration to nursing women is not recommended as codeine may be secreted in breast milk and may cause respiratory depression in the infant.
4.7. Effects on ability to drive and use machines
Codeine may cause drowsiness. Patients receiving this medication should not drive or operate machinery unless it has been shown not to affect mental or physical ability.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called 'statutory defence') if:
o The medicine has been prescribed to treat a medical or dental problem and
o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and
o It was not affecting your ability to drive safely
4.8. Undesirable effects
Gastrointestinal side effects, constipation is not uncommon; loss of appetite; flushing of face might occasionally occur; respiratory depression may be experienced; sputum retention may occur particularly in patients with chronic bronchitis and bronchiectasis.
Frequency not known: Pancreatitis.
Hepatobiliary disorders:
Frequency not known: sphincter of Oddi dysfunction.
Psychiatric disorders:
Frequency unknown: Drug dependence (see section 4.4).
General disorders and administration site conditions:
Uncommon: drug withdrawal syndrome.
Drug dependence
Repeated use of Codeine Linctus BP can lead to drug dependence, even at therapeutic doses. The risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.
The effects in overdosage will be potentiated by simultaneous ingestion of alcohol and psychotropic drugs.
Symptoms
Respiratory depression may develop but is unlikely to be severe unless other sedative agents have been co-ingested, including alcohol, or the overdose is very large. The pupils may be pin-point in size, nausea and vomiting are common. Hypotension and tachycardia are possible but unlikely.
Management
This should include general symptomatic and supportive measures including a clear airway and monitoring vital signs until stable. Consider administering activated charcoal if an adult presents within one hour of ingestion of more than 350 mg or if more than 2.5 mg/kg (in adults and children) has been ingested.
Give naloxone if respiratory depression is present. Naloxone is a competitive antagonist and has a short half-life. So large and repeated doses of naloxone may be required in a seriously poisoned patient. Observe for at least four hours after ingestion, or eight hours if a sustained release preparation has been taken.
🇷🇴 Known in Romania as
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
- CODEINA FOSFAT LPH 15 mg prescriptionCODEINUM · taken by mouth
- FOSFAT DE CODEINA BIOEEL 15 mg prescriptionCODEINUM · taken by mouth
- CODEINA SLAVIA 15 mg prescriptionCODEINUM · taken by mouth
- CODEINA FOSFAT MCC 15 mg prescriptionCODEINUM · taken by mouth
- FOSFAT DE CODEINA SINTOFARM 15 mg prescriptionCODEINUM · taken by mouth
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
🇵🇱 Known in Poland as
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Not the same combination. This medicine contains Codeine phosphate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
- Neoazarina partial — not the same combinationThymi herba pulveratum + Codeini phosphas hemihydricus · taken by mouth
- HERBAPini partial — not the same combinationPini extractum fluidum + Foeniculi tinctura + Codeini phosphas hemihydricus · taken by mouth
- Sirupus Pini compositus partial — not the same combinationPini extractum fluidum + Foeniculi tinctura + Codeini phosphas hemihydricus · taken by mouth
- Solpadeine partial — not the same combinationParacetamolum + Coffeinum + Codeini phosphas · taken by mouth
- Syrop sosnowy złożony Aflofarm partial — not the same combinationPini extractum fluidum + Anisi tinctura + Codeini phosphas hemihydricus · taken by mouth
- Thiocodin partial — not the same combinationCodeini phosphas hemihydricus + Sulfogaiacolum · taken by mouth
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
💬 Ask about this leaflet
Ask anything about Codeine Linctus BP. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.